PepGen Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
PEPG$4.61+92.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OFCASH FLOWS
(IN THOUSANDS)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(30,202) | $(18,020) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation | 388 | 376 |
| Stock-based compensation expense | 3,432 | 2,022 |
| Amortization and interest accretion related to operating lease | 937 | (135) |
| Amortization and accretion of premium and discounts on marketable securities, net | (696) | (516) |
| Other non-cash adjustments | 11 | 20 |
| Changes in operating assets and liabilities: | ||
| Prepaids and other current and non-current assets | 304 | 62 |
| Accounts payable | 943 | 88 |
| Accrued expenses and other non-current liabilities | 2,711 | (6,765) |
| Operating lease liabilities, current and non-current | (758) | 336 |
| Net cash used in operating activities | $(22,930) | $(22,532) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | $(125) | $(53) |
| Purchases of marketable securities | (6,726) | (29,239) |
| Maturities of marketable securities | 24,000 | 18,000 |
| Net cash provided by (used in) investing activities | $17,149 | $(11,292) |
| Cash flows from financing activities: | ||
| Issuance of common stock in public offering, net of underwriters' fees | $— | $76,878 |
| Payment of offering costs | — | (206) |
| Issuance of common stock from At-the-Market Sales Agreement, net of underwriters' fees | — | 9,900 |
| Proceeds from employee equity plans | — | 395 |
| Net cash provided by financing activities | $— | $86,967 |
| Effect of exchange rate changes on cash | (7) | (63) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | $(5,788) | $53,080 |
| Cash, cash equivalents and restricted cash at beginning of period | 50,969 | 82,322 |
| Cash, cash equivalents and restricted cash at end of period | $45,181 | $135,402 |
| Components of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $43,633 | $133,854 |
| Restricted cash | 1,548 | 1,548 |
| Total cash, cash equivalents and restricted cash at end of period | $45,181 | $135,402 |
| Supplemental noncash investing and financing activities: | ||
| Property and equipment included in accounts payable and accrued expenses | $64 | $19 |
| Deferred offering costs in accounts payable and accrued expenses | $— | $188 |
| Cash paid for taxes | $86 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.